- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1286770-55-5] Verubecestat
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-16759 |
| Brand: | MCE |
| CAS: | 1286770-55-5 |
Overview
| MDL | MFCD28963974 |
|---|---|
| Molecular Weight | 409.41 |
| Molecular Formula | C17H17F2N5O3S |
| SMILES | O=C(C1=NC=C(F)C=C1)NC2=CC=C(F)C([C@@](C3)(C)N=C(N)N(C)S3(=O)=O)=C2 |
1 Publications Citing Use of MCE
Summary
IC50 & Target
Ki: 2.2 nM (BACE1) and 0.38 nM (BACE2) [1]
In Vitro
Verubecestat (MK-8931) is a β-site amyloid precursor protein cleaving enzyme 1/2 (BACE1/2) inhibitor. Verubecestat does not significantly inhibit human CYP isoforms 1A2, 2C9, 2C19, 2D6, and 3A4 (all IC
50
>40 μM), indicating that the compound is unlikely to be a perpetrator of CYP-mediated drug-drug interactions
[1]
.
Verubecestat has IC
50
s of 2.1 nM, 0.7 nM, 4.4 nM for Aβ1-40, Aβ1-42, sAPPβ in HEK293 APP
Swe/Lon
cells
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Verubecestat (MK-8931; 3 mg/kg; IV or oral) has a T
1/2
of 1.9 hours, a CL of 46 mL/min/kg, a V
ss
of 5.4 L/kg, a C
max
of 0.27 μM and a AUC of 1.1 μM•h for Sprague-Dawley (SD) rats
[1]
.
Verubecestat (1 mg/kg; IV) has a T
1/2
of 4.9 hours, a CL of 21 mL/min/kg, a V
ss
of 7.5 L/kg for cynomolgus monkeys
[1]
.
Verubecestat (1 mg/kg; IV) has a T
1/2
of 9.7 hours, a CL of 4.3 mL/min/kg, a V
ss
of 2.7 L/kg for beagle dogs
[1]
.
Verubecestat (30 mg/kg; orally; BID for 5 days) causes a modest (1.4-fold) induction of CYP 3A1 activity but does not significantly alter the expression of CYPs 1A1, 1A2, 2B, 3A2, or 4A in rats
[1]
.
Verubecestat dose-dependently reduces CSF and cortex Aβ40 with ED
50
values of 5 and 8 mg/kg, respectively, corresponding to unbound plasma EC
50
values of 48 and 81 nM, respectively
[1]
.
Verubecestat (3 and 10 mg/kg; orally) reduces profound, sustained of CSF Aβ40 levels and has peak effects on CSF Aβ lowering (72 and 81% reduction at 3 and 10 mg/kg, respectively) 12 h after dosing
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Sprague-Dawley (SD) rats [1] |
| Dosage: | 3 mg/kg (Pharmacokinetic Analysis) |
| Administration: | IV or oral |
| Result: | Had a T 1/2 of 1.9 hours, a CL of 46 mL/min/kg, a V ss of 5.4 L/kg, a C max of 0.27 μM and a AUC of 1.1 μM•h. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01537757 | Merck Sharp & Dohme LLC |
Alzheimer´s Disease
|
March 2012 | Phase 1 |
| NCT01953601 | Merck Sharp & Dohme LLC |
Amnestic Mild Cognitive Impairment|Alzheimer´s Disease|Prodromal Alzheimer´s Disease
|
November 5, 2013 | Phase 3 |
| NCT01496170 | Merck Sharp & Dohme LLC |
Alzheimer´s Disease
|
December 2011 | Phase 1 |
| NCT02910739 | Merck Sharp & Dohme LLC |
Amnestic Mild Cognitive Impairment|Alzheimer´s Disease|Prodromal Alzheimer´s Disease
|
October 11, 2016 | Phase 1 |
| NCT01739348 | Merck Sharp & Dohme LLC |
Alzheimer´s Disease
|
November 30, 2012 | Phase 2|Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 35 mg/mL ( 85.49 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4425 mL | 12.2127 mL | 24.4254 mL |
| 5 mM | 0.4885 mL | 2.4425 mL | 4.8851 mL |
| 10 mM | 0.2443 mL | 1.2213 mL | 2.4425 mL |
References
- [1] Scott JD, et al. Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer'sDisease. Med Chem. 2016 Dec 8;59(23):10435-10450.
- [2] Yan R, et al. Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs. Transl Neurodegener. 2016 Jul 14;5:13.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.